vs
查尔斯河实验室（CRL）与Healthpeak Properties（DOC）财务数据对比。点击上方公司名可切换其他公司
查尔斯河实验室的季度营收约是Healthpeak Properties的1.4倍（$994.2M vs $719.4M），Healthpeak Properties净利率更高（73.2% vs -27.8%，领先101.0%），Healthpeak Properties同比增速更快（3.1% vs -0.8%），Healthpeak Properties自由现金流更多（$357.0M vs $58.6M），过去两年Healthpeak Properties的营收复合增速更高（8.9% vs -0.9%）
查尔斯河实验室国际是总部位于美国马萨诸塞州威尔明顿的医药及生物技术领域合同研究组织（CRO），成立于1947年，可为新药、疫苗及医疗器械的研发提供临床前和临床阶段的专业实验室服务。
Healthpeak Properties是美国医疗地产领域的房地产投资信托基金，核心投资范畴覆盖老年住宅、生命科学相关物业及医疗办公楼三类资产。公司2007年于马里兰州组建，总部设在科罗拉多州丹佛市，在尔湾、纳什维尔、旧金山均设有办事处，截至2019年12月31日共持有617处物业的权益。
CRL vs DOC — 直观对比
营收规模更大
CRL
是对方的1.4倍
$719.4M
营收增速更快
DOC
高出3.9%
-0.8%
净利率更高
DOC
高出101.0%
-27.8%
自由现金流更多
DOC
多$298.4M
$58.6M
两年增速更快
DOC
近两年复合增速
-0.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $994.2M | $719.4M |
| 净利润 | $-276.6M | $114.0M |
| 毛利率 | — | — |
| 营业利润率 | -28.5% | 17.4% |
| 净利率 | -27.8% | 73.2% |
| 营收同比 | -0.8% | 3.1% |
| 净利润同比 | -28.9% | 2406.4% |
| 每股收益（稀释后） | $-5.57 | $0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRLDOC
| Q4 25 | $994.2M | $719.4M | ||
| Q3 25 | $1.0B | $705.9M | ||
| Q2 25 | $1.0B | $694.3M | ||
| Q1 25 | $984.2M | $702.9M | ||
| Q4 24 | $1.0B | $698.0M | ||
| Q3 24 | $1.0B | $700.4M | ||
| Q2 24 | $1.0B | $695.5M | ||
| Q1 24 | $1.0B | $606.6M |
净利润CRLDOC
| Q4 25 | $-276.6M | $114.0M | ||
| Q3 25 | $54.4M | $-117.1M | ||
| Q2 25 | $52.3M | $31.7M | ||
| Q1 25 | $25.5M | $42.8M | ||
| Q4 24 | $-214.5M | $4.5M | ||
| Q3 24 | $69.7M | $85.9M | ||
| Q2 24 | $94.1M | $146.0M | ||
| Q1 24 | $73.0M | $6.7M |
毛利率CRLDOC
| Q4 25 | — | — | ||
| Q3 25 | — | 58.6% | ||
| Q2 25 | — | 60.2% | ||
| Q1 25 | — | 61.1% | ||
| Q4 24 | — | 60.3% | ||
| Q3 24 | 34.6% | 60.0% | ||
| Q2 24 | 34.5% | 60.6% | ||
| Q1 24 | 34.1% | 59.8% |
营业利润率CRLDOC
| Q4 25 | -28.5% | 17.4% | ||
| Q3 25 | 13.3% | 9.2% | ||
| Q2 25 | 9.7% | 5.7% | ||
| Q1 25 | 7.6% | 7.7% | ||
| Q4 24 | -16.7% | -2.2% | ||
| Q3 24 | 11.6% | 14.1% | ||
| Q2 24 | 14.8% | 22.3% | ||
| Q1 24 | 12.5% | 3.7% |
净利率CRLDOC
| Q4 25 | -27.8% | 73.2% | ||
| Q3 25 | 5.4% | -16.6% | ||
| Q2 25 | 5.1% | 4.6% | ||
| Q1 25 | 2.6% | 6.1% | ||
| Q4 24 | -21.4% | 0.7% | ||
| Q3 24 | 6.9% | 12.3% | ||
| Q2 24 | 9.2% | 21.0% | ||
| Q1 24 | 7.2% | 1.1% |
每股收益（稀释后）CRLDOC
| Q4 25 | $-5.57 | $0.16 | ||
| Q3 25 | $1.10 | $-0.17 | ||
| Q2 25 | $1.06 | $0.05 | ||
| Q1 25 | $0.50 | $0.06 | ||
| Q4 24 | $-4.17 | $0.02 | ||
| Q3 24 | $1.33 | $0.12 | ||
| Q2 24 | $1.74 | $0.21 | ||
| Q1 24 | $1.30 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $213.8M | $467.5M |
| 总债务越低越好 | $2.1B | $9.8B |
| 股东权益账面价值 | $3.2B | $7.5B |
| 总资产 | $7.1B | $20.3B |
| 负债/权益比越低杠杆越低 | 0.68× | 1.31× |
8季度趋势，按日历期对齐
现金及短期投资CRLDOC
| Q4 25 | $213.8M | $467.5M | ||
| Q3 25 | $207.1M | $91.0M | ||
| Q2 25 | $182.8M | $89.4M | ||
| Q1 25 | $229.4M | $70.6M | ||
| Q4 24 | $194.6M | $119.8M | ||
| Q3 24 | $210.2M | $180.4M | ||
| Q2 24 | $179.2M | $106.9M | ||
| Q1 24 | $327.0M | $101.8M |
总债务CRLDOC
| Q4 25 | $2.1B | $9.8B | ||
| Q3 25 | $2.2B | $9.1B | ||
| Q2 25 | $2.3B | $9.0B | ||
| Q1 25 | $2.5B | $8.9B | ||
| Q4 24 | $2.2B | $8.7B | ||
| Q3 24 | $2.3B | $8.6B | ||
| Q2 24 | $2.4B | $8.6B | ||
| Q1 24 | $2.7B | $8.8B |
股东权益CRLDOC
| Q4 25 | $3.2B | $7.5B | ||
| Q3 25 | $3.4B | $7.6B | ||
| Q2 25 | $3.4B | $7.9B | ||
| Q1 25 | $3.2B | $8.2B | ||
| Q4 24 | $3.5B | $8.4B | ||
| Q3 24 | $3.8B | $8.6B | ||
| Q2 24 | $3.7B | $8.8B | ||
| Q1 24 | $3.6B | $8.9B |
总资产CRLDOC
| Q4 25 | $7.1B | $20.3B | ||
| Q3 25 | $7.5B | $19.6B | ||
| Q2 25 | $7.6B | $19.8B | ||
| Q1 25 | $7.6B | $19.8B | ||
| Q4 24 | $7.5B | $19.9B | ||
| Q3 24 | $8.0B | $20.0B | ||
| Q2 24 | $7.9B | $20.2B | ||
| Q1 24 | $8.2B | $20.5B |
负债/权益比CRLDOC
| Q4 25 | 0.68× | 1.31× | ||
| Q3 25 | 0.64× | 1.20× | ||
| Q2 25 | 0.70× | 1.14× | ||
| Q1 25 | 0.79× | 1.08× | ||
| Q4 24 | 0.65× | 1.04× | ||
| Q3 24 | 0.62× | 1.00× | ||
| Q2 24 | 0.65× | 0.98× | ||
| Q1 24 | 0.73× | 0.99× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $147.5M | $1.3B |
| 自由现金流经营现金流 - 资本支出 | $58.6M | $357.0M |
| 自由现金流率自由现金流/营收 | 5.9% | 49.6% |
| 资本支出强度资本支出/营收 | 8.9% | 124.4% |
| 现金转化率经营现金流/净利润 | — | 10.99× |
| 过去12个月自由现金流最近4个季度 | $518.5M | — |
8季度趋势，按日历期对齐
经营现金流CRLDOC
| Q4 25 | $147.5M | $1.3B | ||
| Q3 25 | $213.8M | $315.0M | ||
| Q2 25 | $204.6M | $363.5M | ||
| Q1 25 | $171.7M | $279.4M | ||
| Q4 24 | $159.4M | $1.1B | ||
| Q3 24 | $251.8M | $318.2M | ||
| Q2 24 | $193.5M | $316.2M | ||
| Q1 24 | $129.9M | $152.6M |
自由现金流CRLDOC
| Q4 25 | $58.6M | $357.0M | ||
| Q3 25 | $178.2M | — | ||
| Q2 25 | $169.3M | — | ||
| Q1 25 | $112.4M | — | ||
| Q4 24 | $83.7M | $333.7M | ||
| Q3 24 | $213.1M | — | ||
| Q2 24 | $154.0M | — | ||
| Q1 24 | $50.7M | — |
自由现金流率CRLDOC
| Q4 25 | 5.9% | 49.6% | ||
| Q3 25 | 17.7% | — | ||
| Q2 25 | 16.4% | — | ||
| Q1 25 | 11.4% | — | ||
| Q4 24 | 8.4% | 47.8% | ||
| Q3 24 | 21.1% | — | ||
| Q2 24 | 15.0% | — | ||
| Q1 24 | 5.0% | — |
资本支出强度CRLDOC
| Q4 25 | 8.9% | 124.4% | ||
| Q3 25 | 3.5% | — | ||
| Q2 25 | 3.4% | — | ||
| Q1 25 | 6.0% | — | ||
| Q4 24 | 7.5% | 105.6% | ||
| Q3 24 | 3.8% | — | ||
| Q2 24 | 3.8% | — | ||
| Q1 24 | 7.8% | — |
现金转化率CRLDOC
| Q4 25 | — | 10.99× | ||
| Q3 25 | 3.93× | — | ||
| Q2 25 | 3.91× | 11.48× | ||
| Q1 25 | 6.74× | 6.52× | ||
| Q4 24 | — | 235.43× | ||
| Q3 24 | 3.61× | 3.71× | ||
| Q2 24 | 2.06× | 2.17× | ||
| Q1 24 | 1.78× | 22.85× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CRL
| Discovery And Safety Assessment Segment | $591.6M | 60% |
| Manufacturing Support Segment | $196.4M | 20% |
| Transferred At Point In Time | $108.0M | 11% |
| Transferred Over Time | $98.3M | 10% |
DOC
暂无分部数据
